乌司奴单抗静脉诱导后峰值浓度可预测克罗恩病内镜与生化缓解
这项前瞻性观察研究纳入41例活动性克罗恩病患者,在乌司奴单抗静脉诱导后2周内监测血清药物浓度,发现峰值浓度与第24周内镜缓解相关,且所有早期暴露参数均与生化缓解相关,提示早期浓度监测或有助于优化治疗。
要点
- 静脉诱导后峰值浓度>105 μg/mL者内镜缓解率46%,<88 μg/mL者仅7%。
- 2周内所有暴露参数均与生化缓解相关,峰值浓度与内镜缓解相关。
- 早期浓度监测可能用于识别最可能达到内镜缓解的克罗恩病患者。
核心结论
- 乌司奴单抗静脉输注后1小时峰值浓度可能用于识别最可能达到内镜缓解的克罗恩病患者。
- 早期浓度监测可能有助于优化克罗恩病治疗。
研究设计与样本
- 前瞻性观察研究,单中心,2017年10月至2019年1月连续纳入41例因内镜活动标志开始乌司奴单抗治疗的克罗恩病患者。
- 给药方案约为6 mg/kg静脉诱导后90 mg每8周,监测2周内乌司奴单抗暴露参数。
主要发现
- 第24周内镜缓解10例(24.4%),第8周生化缓解17例(41.5%),第16周17例(41.5%),第24周21例(51.2%)。
- 峰值浓度与内镜缓解相关,ROC曲线下面积0.717(95%CI 0.517-0.916)。
- 峰值浓度>105 μg/mL(上三分位)者13例中6例(46%)达到内镜缓解,<88 μg/mL(下三分位)者14例中仅1例(7%)达到内镜缓解。
- 2周内所有暴露参数均与生化缓解相关,峰值浓度、第2周浓度、2周AUC及第4、8周暴露指标与生化或内镜缓解的关联无显著差异。
关键数值与推荐
- 内镜缓解定义为简化克罗恩病内镜评分≤3且无溃疡,由中心评估。
- 生化缓解定义为粪钙卫蛋白<100 mg/kg。
临床怎么用
- 可考虑在乌司奴单抗静脉诱导后早期(如输注后1小时)监测峰值浓度,以识别内镜缓解可能性较高的患者。
- 早期浓度监测或可作为优化克罗恩病治疗的参考依据。
局限性
- 单中心、样本量较小(41例),观察性设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Little is known about the relationship between ustekinumab exposure during the first 2 weeks of treatment and outcomes of patients with Crohn's disease (CD). We investigated the relationship between serum concentrations of ustekinumab during the first 2 weeks of treatment and endoscopic and biochemical remission in patients with CD. METHODS: In a prospective observational study, we measured concentrations of ustekinumab in serum samples from 41 consecutive patients who started treatment with ustekinumab (approximately 6 mg/kg, intravenously, then 90 mg every 8 weeks), due to endoscopic markers of active CD, at a single center from October 2017 through January 2019. We measured ustekinumab exposure parameters during the first 2 weeks (peak concentration measured immediately after intravenous infusion, week 2 concentration, and area under the curve through week 2). We investigated the correlation between these parameters and endoscopic remission (simple endoscopic score for CD scores of 3 or less without ulceration, assessed centrally) and biochemical remission (level of fecal calprotectin below 100 mg/kg) using the Mann-Whitney U test. RESULTS: Endoscopic remission was achieved in 10 patients (24.4%) at week 24; biochemical remission was achieved in 17 patients (41.5%) at week 8, 17 patients (41.5%) at week 16, and 21 patients (51.2%) at week 24. Peak concentrations associated with endoscopic remission (area under the receiver operating characteristic curve, 0.717; 95% CI, 0.517-0.916); 6 of 13 patients (46%) with peak concentrations above 105 μg/mL (upper tercile) achieved endoscopic remission, compared with only 1 of 14 patients (7%) with peak concentrations below 88 μg/mL (lower tercile). All exposure parameters during the first 2 weeks were associated with biochemical remission. There was no significant difference between the associations of peak concentrations, week-2 concentrations, area under the curve through week 2, or later exposure measures (at weeks 4 and 8) with biochemical or endoscopic remission. CONCLUSIONS: In a prospective study, we found that serum concentrations of ustekinumab as early as 1 hour after intravenous infusion might be used to identify patients with CD most likely to achieve endoscopic remission. This early measurement might be used to optimize treatment of CD.
引用
- Hanžel J, Zdovc J, Kurent T, et al. Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission. Clin Gastroenterol Hepatol. 2020. PMID: 32109630. doi:10.1016/j.cgh.2020.02.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。